



Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8

Jan 04, 2018

GHENT, Belgium, Jan. 4, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of [Intrexon Corporation](#) (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Pieter Rottiers, PhD, ActoBio's Chief Executive Officer, will present at the Biotech Showcase 2018 Conference in San Francisco on Monday, January 8th at 2 p.m. Pacific Time. The presentation will highlight the innovative, proprietary ActoBiotics[®] drug delivery platform for oral and topical administration of biologicals to address unmet medical needs for diverse health indications.

"ActoBio Therapeutics combines world-class science, preclinical and clinical-stage products, and a leadership team with over 20 years hands-on experience developing the platform. ActoBio has reached a significant level of development and is well prepared to move forward to create significant new therapeutic modalities across a broad set of markets with strong growth dynamics including oral, gastrointestinal, and autoimmune/allergic disorders. Using the innovative ActoBiotics[®] platform, we have built a strong R&D pipeline with the latest stage therapeutic candidate in Phase 2b and an extensive portfolio of candidates both partnered and self-owned ready for clinical development across a number of conditions," Dr. Rottiers commented.



A live webcast of the presentation will be available on the Investors section of Intrexon's website at <http://investors.dna.com/events>. Replay of the webcast will be available for 30 days following the event.

About ActoBio Therapeutics, Inc.

ActoBio Therapeutics, Inc. is pioneering a new class of microbe-based ActoBiotics[®] biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The ActoBiotics[®] platform produces biologics through oral or topical administration with treatment applications across many diseases including oral, gastrointestinal, and autoimmune/allergic disorders. This cost-effective approach is being developed to provide safer and more efficacious treatments than injectable biologicals. ActoBio Therapeutics has a strong R&D pipeline with the latest stage candidate in Phase 2b and an extensive portfolio of candidates ready for clinical development across a number of potential indications.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA[™] to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. Intrexon calls its synthetic biology approach Better DNA[®], and invites you to discover more at www.dna.com or follow us on Twitter at [@Intrexon](#), on [Facebook](#), and [LinkedIn](#).

Trademarks

Intrexon, ActoBio Therapeutics, ActoBiotics, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information, contact:

Media Contact:

Kekst and Company

Adam Weiner/ Robert Siegfried

Tel: +1 (212) 521-4823 / +1 (212) 521-4832

Investor Contact:

Thomas Shrader, PhD
Vice President, Communications & Strategy
Intrexon Corporation
investors@intrexon.com

Corporate Contact:

Marie Rossi, PhD
Director, Technical Communications
Intrexon Corporation
Tel: +1 (301) 556-9850
publicrelations@intrexon.com

SOURCE Intrexon Corporation; ActoBio Therapeutics, Inc.